Haisco(SZ:002653) 智通财经网·2025-09-03 08:04Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HSK47388 tablets, a drug developed for the treatment of autoimmune diseases [1] Company Summary - HSK47388 tablets are an orally administered, potent, and highly selective drug developed by the company [1] - The drug has shown significant efficacy in preclinical studies, particularly in a rat model of colitis, demonstrating dose-dependent effects [1] - HSK47388 exhibits good tolerability and a large safety window, indicating its potential for further development [1] Industry Summary - The approval for clinical trials represents a new indication for HSK47388 in the field of autoimmune diseases, potentially providing a new treatment option for patients [1]